About PTC Therapeutics
PTC Therapeutics is a publicly listed company based in South Plainfield (United States) founded in 1998. Small molecule drugs for rare diseases are developed. PTC Therapeutics has raised $248.1 million across 23 funding rounds from investors including Amgen, Novartis and Credit Suisse. The company has 939 employees. PTC Therapeutics has completed 2 acquisitions, including Agilis Biotherapeutics and Censa Pharmaceuticals. Its website ptcbio.com draws about 24 thousand monthly visits. PTC Therapeutics offers products and services including SMA Treatments, DMD Treatments, and PKU Treatments. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is PTC Therapeutics, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, United States. Focus is placed on the development of small molecule drugs targeting rare diseases, with operations centered in the biotechnology sector. The lead product, Ataluren, is administered orally to address cystic fibrosis and Duchenne muscular dystrophy linked to nonsense mutations. Additional efforts are directed toward anticancer and antibacterial therapeutics.
- Headquarters South Plainfield, United States
- Employees 939
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website ptcbio.com
- Social LinkedIn X Facebook Instagram
- Legal Name Ptc Therapeutics, Inc.
- Annual Revenue$1.73 B (USD)114.51as on Dec 31, 2025
- Net Profit$682.64 M (USD)as on Dec 31, 2025
- EBITDA$895.32 M (USD)as on Dec 31, 2025
- Total Equity Funding$248.1M (USD)
in 23 rounds
- Latest Funding Round$35.9M (USD), Post-IPO
May 2023
- InvestorsAmgen
& 23 more
- Employee Count939
- Investments & AcquisitionsAgilis Biotherapeutics
& 1 more
Products & Services of PTC Therapeutics
PTC Therapeutics offers a comprehensive portfolio of products and services, including SMA Treatments, DMD Treatments, and PKU Treatments.
Medications for spinal muscular atrophy to enhance motor function.
Therapies for Duchenne muscular dystrophy to slow progression.
Solutions for phenylketonuria to manage metabolic issues.
Funding Insights of PTC Therapeutics
PTC Therapeutics has successfully raised a total of $248.1M across 23 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35.9 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $248.1M
- Total Rounds 23
- Last Round Post-IPO — $35.9M
- First Round $40M
(Sep 2001)
- Investors Count 24
Latest 10 of 23 funding rounds of PTC Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $35.9M | Post-IPO | – | – | – |
| May 2020 | $140.95M | Post-IPO | – | – | – |
| Sep 2019 | $250M | Post-IPO | – | – | – |
| Mar 2018 | $108.2M | Post-IPO | – | – | – |
| Jun 2017 | Post-IPO | – | – | ||
| Aug 2015 | $150M | Post-IPO | – | – | – |
| May 2013 | $4.5M | Series J | – | – | – |
| Mar 2013 | $60M | Series J | – | Brookside Capital | |
| Feb 2013 | $2M | Series G | – | – | – |
| Sep 2012 | $1.08M | Grant | – | – |
24 investors in total: 24 institutional.
Investors in PTC Therapeutics
PTC Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Novartis and Credit Suisse.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Venture capital firm focused on multiple sectors | brooksidecapital.com | San Francisco, United States | ||
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
Investments are made in life sciences firms across all stages. | delphiventures.com | Menlo Park, United States | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Private equity investments are backed by a single-family office firm. | capital.vulcan.com | Seattle, United States | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
| healthcap.eu |
Investor details for PTC Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PTC Therapeutics
244 people are tracked at PTC Therapeutics (129 in leadership, 10 in board & advisors, 105 in team); the tracked headcount is 939.
| Name | Role | Group |
|---|---|---|
Neil Almstead | Chief Technical Operations Officer | Leadership |
Eric Pauwels | Chief Business Officer | Leadership |
Colin Molloy | Finance Business Partner, Regional Commercial And Medical Affairs. | Leadership |
Yacine M. Amrani | Senior Director Business Development | Leadership |
Heidi Varghese | Associate Director R&d Finance | Leadership |
Matthew B. Klein | CEO | Leadership |
Niclas Stridsberg | Director Commercial Operations | Leadership |
Lee Golden | Svp, Chief Medical Officer | Leadership |
Laura Franceschetti | Associate Director Medical Affairs, Italy | Leadership |
James Takasugi | Executive Director, API Process Development | Leadership |
Jacqueline Demartino | Associate Director, Corporate Accounting | Leadership |
Lorraine Bracy-Ward | Director, Global Legal Operations | Leadership |
Eduardo Alcantara | Director, IT Project Management And Computer Systems Validation At PTC Therapeutics, Inc. | Leadership |
Luciana Nishi Antonello | Director Pharmacovigilance | Leadership |
Amanda Reynolds | Senior Director, Pharmacovigilance | Leadership |
Hannah Brennan | Associate Director, Medical Information | Leadership |
Peter Giannousis | VP Chemical Process Development | Leadership |
Janet Wang | Chief Of Staff - Cmc, Technical Operations And Research | Leadership |
Lori Semeraro | Senior Director Quality Assurance GXP | Leadership |
Aurora E. Flores | Associate Director, US Patient Engagement | Leadership |
224 more people are available in the full profile.
Complete people profiles for PTC Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of PTC Therapeutics
PTC Therapeutics is a publicly listed company on the NASDAQ with ticker symbol PTCT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Jun 2013
- Listed onNASDAQ: PTCT
- Listed entityPTC Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS69366J2006
- Share price$59.92 (-4.77% on the day) · 2026-10-13
- Market capitalisation$5.00B
- Price to earnings9.1
- EPS (diluted, trailing year)$-0.59
- Volume (last session)1,051,413
Financials of PTC Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.73B | $682.6M | $895.3M |
| 2024 | $806.8M | -$363.3M | -$71.1M |
| 2023 | $937.8M | -$626.6M | -$112.8M |
| 2022 | $698.8M | -$559.0M | -$311.1M |
| 2021 | $538.6M | -$523.9M | -$303.4M |
Detailed financial statements for PTC Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PTC Therapeutics
PTC Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Agilis Biotherapeutics and Censa Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drugs for Tetrahydrobiopterin deficiency and rare CNS disorders are developed. | censapharma.com | Cambridge, United States | 2015 | May 2020 | $539M | |
Gene therapy platform for rare monogenic CNS diseases is developed. | agilisbio.com | Cambridge, United States | 2013 | Jul 2018 | $200M |
Complete acquisition details for PTC Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of PTC Therapeutics
6 dated milestones of PTC Therapeutics across 25 years, from founding to its latest funding, stage changes and deals.
- Founded PTC Therapeutics is founded.
- Funding First funding round of $40.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Agilis Biotherapeutics.
- Acquisition Acquires Censa Pharmaceuticals.
- Funding Latest funding round, Post-IPO, of $35.9M.
Competitors of PTC Therapeutics
PTC Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of PTC Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PTC Therapeutics
The website of PTC Therapeutics (ptcbio.com) receives about 24.4K visits a month and ranks #1,154,739 among all websites worldwide, #1,446 in Biotechnology and Pharmaceuticals.
- Monthly visits24.4K
▼ 6.5% vs previous month
- Unique visitors10.5K
per month
- Global rank#1,154,739
among all websites
- Category rank#1,446
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.7
- Average visit17 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with PTC Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| enanta.com | 100% | 5.6K | #4,030,810 | View details | |
| biocentury.com | 100% | 85.7K | #514,907 | View details | |
ophthotech.com | ophthotech.com | 99% | – | ||
| morphotek.com | 92% | View details | |||
precisiontherapeutics.com | precisiontherapeutics.com | 91% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for PTC Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as PTC Therapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ptc Therapeutics
Complete news archive for PTC Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PTC Therapeutics
PTC Therapeutics was founded in 1998 and raised its 1st funding round 3 years after it was founded.
PTC Therapeutics is headquartered in South Plainfield, United States. It is registered at South Plainfield, New Jersey, United States.
PTC Therapeutics is a funded company, having raised a total of $248.1M across 23 funding rounds to date. The company's 1st funding round was a Grant of $1.08M, raised on Sep 2001.
PTC Therapeutics has 939 employees.
Annual revenue of PTC Therapeutics is $1.73B as on Dec 31, 2025.
PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, United States. Focus is placed on the development of small molecule drugs targeting rare diseases, with operations centered in the biotechnology sector. The lead product, Ataluren, is administered orally to address cystic fibrosis and Duchenne muscular dystrophy linked to nonsense mutations. Additional efforts are directed toward anticancer and antibacterial therapeutics.
PTC Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
PTC Therapeutics offers SMA Treatments, DMD Treatments, and PKU Treatments.
Yes, PTC Therapeutics is publicly traded on NASDAQ under the ticker symbol PTCT.
PTC Therapeutics has made 2 acquisitions, including Agilis Biotherapeutics, and Censa Pharmaceuticals.
PTC Therapeutics has 24 investors. Key investors include Amgen, Novartis, Credit Suisse, Manulife, and HHS.
PTC Therapeutics operates through Ptc Therapeutics, Inc..